Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of VMP followed by Rd versus KRd with or without daratumumab in fit older adults with newly diagnosed multiple myeloma
2024-516905-22-00Phase 3Authorised
- Sponsor
- PETHEMA
- Start
- Oct 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bortezomib, melphalan, prednisone, lenalidomide, dexamethasone and 2 more in multiple myeloma (MM) (3 arms), sponsored by PETHEMA. Primary endpoint: Immunophenotypic complete response after 18 cycles. Planned start Oct 2018; status: authorised.
02
Drugs
bortezomibmelphalanprednisonelenalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2024-516905-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516905-22-00.